Navigation Links
New cell transplantation technique restores insulin production in diabetics

Researchers are using a new cell transplantation technique to restore the cells that produce insulin in patients with type 1 diabetes. The method is minimally invasive, with few complications. The study was presented today at the annual meeting of the Radiological Society of North America (RSNA).

"We used ultrasound guidance to inject donor cells into the portal vein of diabetic patients, which is accessed through the skin," said co-author Saravanan Krishnamoorthy, M.D., radiology resident at the University of Minnesota in Minneapolis. "This is a safe method of cell transplantation that could potentially become a same-day procedure."

In type 1 diabetes, the body does not produce insulin. This typically results from the destruction of insulin-producing islet beta cells in the pancreas. Insulin is necessary to metabolize sugar, which is the basic fuel that all cells need.

With this minimally invasive technique, donor islet cells are injected into diabetic patients so that the new, healthy islet cells can restore insulin production, essentially stopping the progression of the disease. The study included 13 patients with poorly controlled type 1 diabetes. Fifteen islet cell transplants were completed-two patients underwent two procedures to achieve correct needle placement.

"We used a steroid-free protocol to suppress the immune system, so that the body accepted the transplanted cells," Dr. Krishnamoorthy said. "We also developed a 'sandwich technique' to close the access site through the skin, where the islet cells are injected. The sandwich technique is so-called because of the layered applications of gelfoam and coil used to close the access site."

Dr. Krishnamoorthy said that even though percutaneous islet cell transplantation is currently an experimental procedure, the sandwich closure is a safe method that prevents many of the complications common to previous techniques used to transplant islet cells. Thirty days after the pr ocedure, all 13 patients were producing insulin without requiring supplemental injections, and none experienced major complications. Liver function tests and blood cell counts were monitored carefully during this time.

In the future, Dr. Krishnamoorthy looks toward the potential use of stem cells for this purpose, and also the development of better immunosuppressive medications to keep the body from rejecting the transplanted islet cells.

Type 1 diabetes, formerly known as juvenile diabetes, is a debilitating disease that is usually diagnosed in children and young adults. It can result in significant morbidity, causing vision loss, loss of sensation that results in severe infections, fractures and amputations, destruction of major organ function (e.g., the kidneys) and cardiovascular disease that can result in complications such as heart attacks. Both genetic and environmental factors contribute to the disease.


'"/>

Source:Radiological Society of North America


Related biology news :

1. Monkeying around to improve organ transplantation
2. Diabetes researchers pioneer islet cell xenotransplantation in primate studies
3. Guiding principles for facial transplantation unveiled
4. Plastic surgeons countdown first full facial transplantation
5. Successful transplantation from pig embryos to mice
6. Researchers create genetically matched embryonic stem cells for transplantation
7. New lab technique identifies high levels of pathogens in therapy pool
8. Brain-mapping technique aids understanding of sleep, wakefulness
9. Study reveals new technique for fingerprinting environmental samples
10. Researchers pioneer new gene therapy technique using natural repair process
11. Newer imaging techniques may lead to over-treatment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/17/2016)... -- Global Market Watch: Primarily supported by ownership ... and Academics) market is to witness a value of US$37.1 ... highest Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen ... period 2014-2020. North America is not ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/14/2016)... 2016  xG Technology, Inc. ("xG" or the "Company") ... communications for use in challenging operating environments, announced its ... Management will hold a conference call to discuss these ... Time (details below). Key Recent Accomplishments ... binding agreement to acquire Vislink Communication Systems. The purchase ...
(Date:6/22/2016)... 2016 On Monday, the Department of Homeland ... share solutions for the Biometric Exit Program. The Request ... Protection (CBP), explains that CBP intends to add biometrics ... the United States , in order to deter ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
Breaking Biology News(10 mins):
(Date:12/9/2016)... ... ... Aditya Humad, Acting CFO of AxioMed and Managing Partner of KICVentures, is ... is now gaining interest from Silicon Valley. “It was satisfying to complete the due ... say that, “We expect interest to continue to rise as AxioMed completes its cleanroom ...
(Date:12/9/2016)... Portage Biotech Inc. ("Portage" or "the Company") (OTC: PTGEF, ... Biohaven has issued today the following press release: ... Dec 9, 2016 - Biohaven Pharmaceutical Holding Company Ltd. ... Food and Drug Administration ("FDA") has granted the Company,s ... an orally dissolving tablet being developed for the treatment ...
(Date:12/8/2016)... La Jolla, CA (PRWEB) , ... December 08, 2016 , ... ... that 2016 was a banner year for team building events, new program offerings and ... focus, which it expanded earlier this year to include groups of over 30 people. ...
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire/ ... presented demonstrating the role of the Breast Cancer ... stage, ER+ breast cancer are most at-risk for ... therapy. Data include results from three studies advancing ... provide information related to tumor biology and inform ...
Breaking Biology Technology: